ZVRA Zevra Therapeutics (ZVRA) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001434647
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
93
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · $61.1K priced
What the filings say about ZVRA
Insiders, 180 days
-$1.3M net sold
3 sellers · 20% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$704.8K
2 notices
Zevra Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, ZEVRA THERAPEUTICS, INC. insiders sold a net $1.3M of stock across 54 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Feb 9, 2026.
- The trade is 4.8% of the 417,225 shares held after it.
- No other insider sold within 30 days.
- 93 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO McFarlane Neil F. sold about $224.9K of ZVRA under a 10b5-1 plan on Oct 12, 2026; 93 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jun 22, 2026.
- The trade is 113.6% of the 37,569 shares held after it.
- 1 other insider sold within 30 days.
- 93 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal & Compliance Thompson Rahsaan sold about $474.8K of ZVRA on Aug 14, 2026; 1 other insider sold within 30 days and 93 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Mar 28, 2025.
- -0.6% median (+0.9% mean) 90-day return after 5 previous buys.
- The trade is 683.3% of the 1,800 shares held after it.
- 1 other insider sold within 30 days.
- 93 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Watton Corey Michael sold about $138.4K of ZVRA on Aug 10, 2026; 1 other insider sold within 30 days and 93 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on May 11, 2026.
- The trade is 43.1% of the 80,235 shares held after it.
- No other insider sold within 30 days.
- 93 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal & Compliance Thompson Rahsaan sold about $438.2K of ZVRA on Jun 22, 2026; 93 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jan 30, 2026.
- The trade is 3.7% of the 48,125 shares held after it.
- No other insider sold within 30 days.
- 93 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal & Compliance Thompson Rahsaan sold about $20.3K of ZVRA on May 11, 2026; 93 funds added in the latest 13F quarter.54 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$1.3M over 180 days
-$838.1K over 90 days
below 65% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
93 funds bought in last quarter
more than 65% of Pharma & Biotech
Revenue
+350.9% year over year
more than 91% of Pharma & Biotech
Margin
78.2% net margin
more than 97% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
11.6% of the float short (float per yahoo 2026-10-27) · 7.1 days to cover · settled 2026-10-15
more than 74% of Pharma & Biotech
What changed in the last 30 days
Oct 13Director NEIL F MCFARLANE filed to sell $227.8K by Oct 12 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 13President and CEO McFarlane Neil F. sold $224.9K under a 10b5-1 plan (Oct 12)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Watch ZVRA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-5.9%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ZVRA: institutional holders (13F)
13F holdings, latest reported quarter
5,108,871 sh
$73.3M
4,915,717 sh
$70.5M
4,785,771 sh
$68.6M
3,594,952 sh
$51.6M
2,638,910 sh
$37.8M
Congress trades in ZVRA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ZVRA planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
NEIL F MCFARLANE
Filed 2026-10-13
$227.8K
RAHSAAN THOMPSON
Filed 2026-08-14
$477.0K
JOHN BODE
Filed 2026-07-08
$156.2K
ZVRA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
AUER GROWTH
$1.7M position · as of 2026-05-31
2.2%
Simplify Propel Opportunities ETF
$966.1K position · as of 2026-06-30
1.3%
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF
$5.3M position · as of 2026-06-30
1.2%
PROFUND VP PHARMACEUTICALS
$138.1K position · as of 2026-06-30
1.2%
Janus Henderson Small Cap Growth Alpha ETF
$2.4M position · as of 2026-07-31
0.7%
Invesco Dorsey Wright Healthcare Momentum ETF
$1.5M position · as of 2026-07-31
0.6%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
1 registered trials, 0 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 2
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Mr.Mc Farlane
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$3.8M
$4.0M
$2.7M
n/a
+95%
2024
$5.4M
$7.3M
$2.0M
n/a
+82%
2022
$2.4M
$1.3M
$1.2M
-59%
n/a
2021
$2.7M
$2.8M
$953.6K
-22%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.3M sold by insiders over 180 days, 93 funds added last quarter, $704.8K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
ZVRA financials
Revenue growth
+350.9%
XBRL, annual
Net margin
78.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$136.1M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ZVRA
| FY Dec 2025 | $106.5M |
| FY Dec 2024 | $23.6M |
| FY Dec 2023 | $27.5M |
| FY Dec 2022 | $10.5M |
| FY Dec 2021 | $28.6M |
| Jun 2026 | $39.7M |
| Mar 2026 | $36.2M |
| Dec 2025 | $34.1M |
| Sep 2025 | $26.1M |
| Jun 2025 | $25.9M |
| Mar 2025 | $20.4M |
| Dec 2024 | $12.0M |
| Sep 2024 | $3.7M |
At each fiscal year end
Single quarter
Net margin, TTM
+42.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ZVRA
| FY Dec 2025 | +78.2% |
| FY Dec 2024 | -446.9% |
| FY Dec 2023 | -167.7% |
| FY Dec 2022 | -256.0% |
| FY Dec 2021 | -29.9% |
| Jun 2026 | +22.1% |
| Mar 2026 | +104.6% |
| Dec 2025 | +35.6% |
| Sep 2025 | -2.1% |
| Jun 2025 | +288.7% |
| Mar 2025 | -15.2% |
| Dec 2024 | -296.8% |
| Sep 2024 | -899.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$32.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ZVRA
| FY Dec 2025 | -$2.4M |
| FY Dec 2024 | -$69.7M |
| FY Dec 2023 | -$33.8M |
| FY Dec 2022 | -$18.8M |
| FY Dec 2021 | $10.3M |
| Jun 2026 | $16.8M |
| Mar 2026 | $6.1M |
| Dec 2025 | $5.5M |
| Sep 2025 | $4.2M |
| Jun 2025 | -$3.8M |
| Mar 2025 | -$8.3M |
| Dec 2024 | -$16.2M |
| Sep 2024 | -$18.1M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity ZVRA
| FY Dec 2025 | 0.40x |
| FY Dec 2024 | 1.50x |
| FY Dec 2023 | 0.08x |
| FY Dec 2022 | 0.90x |
| FY Dec 2021 | 0.67x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.40x |
| Sep 2025 | 0.46x |
| Jun 2025 | 0.52x |
| Mar 2025 | 1.46x |
| Dec 2024 | 1.50x |
| Sep 2024 | 0.84x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt ZVRA
| FY Dec 2025 | -0.03x |
| FY Dec 2024 | -1.17x |
| FY Dec 2023 | -6.62x |
| FY Dec 2022 | -0.28x |
| FY Dec 2021 | 0.15x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -0.03x |
| Sep 2025 | -0.38x |
| Jun 2025 | -0.76x |
| Mar 2025 | -1.03x |
| Dec 2024 | -1.17x |
| Sep 2024 | -1.18x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+34.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ZVRA
| FY Dec 2025 | +85.7% |
| FY Dec 2024 | -207.8% |
| FY Dec 2023 | -67.2% |
| FY Dec 2022 | -30.3% |
| FY Dec 2021 | -48.5% |
| Jun 2026 | +34.8% |
| Mar 2026 | +100.7% |
| Dec 2025 | +85.7% |
| Sep 2025 | +34.8% |
| Jun 2025 | +3.5% |
| Mar 2025 | -204.8% |
| Dec 2024 | -207.8% |
| Sep 2024 | -136.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+20.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ZVRA
| FY Dec 2025 | +36.0% |
| FY Dec 2024 | -60.2% |
| FY Dec 2023 | -32.0% |
| FY Dec 2022 | -21.6% |
| FY Dec 2021 | -11.9% |
| Jun 2026 | +20.8% |
| Mar 2026 | +55.1% |
| Dec 2025 | +36.0% |
| Sep 2025 | +15.3% |
| Jun 2025 | +1.3% |
| Mar 2025 | -56.8% |
| Dec 2024 | -60.2% |
| Sep 2024 | -54.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+97.7%
operating income after a 15.9% effective tax rate, over long-term debt only, 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital ZVRA
| FY Dec 2025 | -54.5% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +97.7% |
| Mar 2026 | -8.9% |
| Dec 2025 | -54.5% |
| Sep 2025 | -53.2% |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+34.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ZVRA
| FY Dec 2025 | -32.3% |
| FY Dec 2024 | -71.7% |
| FY Dec 2023 | -49.1% |
| FY Dec 2022 | -36.7% |
| FY Dec 2021 | +11.7% |
| Jun 2026 | +34.2% |
| Mar 2026 | -2.9% |
| Dec 2025 | -32.3% |
| Sep 2025 | -43.7% |
| Jun 2025 | -69.8% |
| Mar 2025 | -53.8% |
| Dec 2024 | -71.7% |
| Sep 2024 | -63.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
10.93x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing ZVRA
| FY Dec 2025 | 6.74x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 15.59x |
| Mar 2026 | 4.68x |
| Dec 2025 | 6.74x |
| Sep 2025 | 21.13x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$451.8M
market value at close 2026-10-27 on 2026-07-31 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value ZVRA
| FY Dec 2025 | $503.9M |
| FY Dec 2024 | $470.9M |
| FY Dec 2023 | $199.2M |
| FY Dec 2022 | $160.6M |
| FY Dec 2021 | $262.9M |
| Jun 2026 | $702.4M |
| Mar 2026 | $451.6M |
| Dec 2025 | $503.9M |
| Sep 2025 | $540.7M |
| Jun 2025 | $494.7M |
| Mar 2025 | $428.1M |
| Dec 2024 | $470.9M |
| Sep 2024 | $370.0M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+5.5%
TTM free cash flow over market value at close 2026-10-27
FCF yield ZVRA
| FY Dec 2025 | -0.5% |
| FY Dec 2024 | -15.6% |
| FY Dec 2023 | -14.3% |
| FY Dec 2022 | -11.9% |
| FY Dec 2021 | +3.4% |
| Jun 2026 | +3.8% |
| Mar 2026 | +2.2% |
| Dec 2025 | -0.5% |
| Sep 2025 | -4.5% |
| Jun 2025 | -9.7% |
| Mar 2025 | -15.3% |
| Dec 2024 | -15.6% |
| Sep 2024 | -19.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing ZVRA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $106.5M | $23.6M | $27.5M | $10.5M |
| Operating income | -$62.9M | -$87.0M | -$49.6M | -$42.6M |
| Net income | $83.2M | -$105.5M | -$46.0M | -$26.8M |
| EPS (diluted) | 1.35 | -2.28 | n/a | n/a |
| Operating cash flow | -$1.6M | -$69.7M | -$33.5M | -$18.7M |
| Cash | $62.4M | $33.8M | $43.0M | $65.5M |
| Long-term debt | $61.9M | $59.5M | $5.1M | n/a |
| Buybacks | n/a | $0 | $3.4M | $4.7M |
SEC XBRL, fiscal years, as known on 2026-10-28
ZVRA Stock Sonar score 6/7 axes
Find similar shapesCompareZVRA ranks highest on financial health (99th percentile) and profitability (95th), and lowest on insider conviction (17th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ZVRA filings, in plain words
Are Zevra Therapeutics insiders buying or selling ZVRA?
In the 180 days to 2026-10-28, Zevra Therapeutics insiders were net sellers, a net $1.3M across purchases and sales reported on Form 4, by 3 sellers.
Are there planned insider sales of ZVRA?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $704.8K of stock; the latest, by NEIL F MCFARLANE, was filed 2026-10-13.
Read the full summary
In the 180 days to 2026-10-28, Zevra Therapeutics insiders were net sellers of ZVRA, a net $1.3M across purchases and sales reported on Form 4 by 3 sellers. 20% of the 5 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $704.8K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
